References
- Flume PA, Mogayzel PJ, Jr., Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802–808.
- Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663–1672.
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2009 Annual Data Report. Available at www.cysticfibrosisdata.org/LiteratureRetrieve.aspx?ID=51547. Accessed June 14, 2016.
- Cystic Fibrosis Foundation Patient Registry: 2014 Annual Data Report. Available at https://www.cff.org/Our-Research/CF-Patient-Registry/. Accessed June 29, 2016.
- Cystic Fibrosis Foundation. Frequently Asked Questions. Available at http://www.cff.org/AboutCF/faqs. Accessed June 14, 2016.
- Fama F, Castagna I, Palamara F, et al. Cystic fibrosis and lens opacity. Ophthalmologica 1998;212:178–179.
- Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. J Cyst Fibros 2004;3:209–222.
- Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995;126:515–523.
- Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8–14.
- Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006;27:1168–1174.
- Hutnik CM, Nichols BD. Cataracts in systemic diseases and syndromes. Curr Opin Ophthalmol 1999;10:22–28.
- Jacques PF, Moeller SM, Hankinson SE, et al. Weight status, abdominal adiposity, diabetes, and early age-related lens opacities. Am J Clin Nutr 2003;78:400–405.
- Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002;85:61–75.
- Mukesh BN, Le A, Dimitrov PN, Ahmed S, et al. Development of cataract and associated risk factors: the Visual Impairment Project. Arch Ophthalmol 2006;124:79–85.
- Congdon N, Vingerling JR, Klein BE, et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004;122:487–494.
- Klein BE, Klein R, Lee KE. Incidence of age-related cataract: the Beaver Dam Eye Study. Arch Ophthalmol 1998;116:219–225.
- Cheung N, Wong TY. Obesity and eye diseases. Surv Ophthalmol 2007;52:180–195.
- Seliger VI, Bai Y, Volkova N, et al. Prevalence of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation. J Cyst Fibros 2015;14:S108.